
Richard Lundin
CEO
Richard brings over 35 years of management experience, primarily in the diagnostics field, with a strong emphasis on transfusion medicine.
Over the course of his career, Richard has developed an extensive skill set, particularly in launching innovative products tailored to clinical laboratories and blood banks.
With in-depth knowledge of public tender processes and a proven ability to excel in cross-functional teams within international environments. In addition to driving sales and marketing initiatives, Richard will dedicate significant time to ensuring that LUNDAIR’s unique blast freezer technology achieves MDR classification.
With a strong commitment to innovation and excellence, Richard is focused on positioning LUNDAIR as a leader inblast freezers for blood plasma, using sustainable and compliant solutions for the industry.

Peter Rybäck
Interim - Finance & Communication
Peter brings over 25 years of experience in the pharmaceutical and healthcare industries to his role as CFO at LUNDAIR. He drives the company’s financial strategy and operational excellence, supporting its mission to innovate blast freezer technology for plasma. With a career rooted in the development and commercialization of hospital solutions, he possesses a deep understanding of market dynamics and the successful launch of innovative products.
Before joining LUNDAIR, Peter co-founded and serves as the Chairman of OptiCell Solutions AB, where he led the growth of a pioneering startup specializing in apheresis technology. This experience further strengthened his ability to lead dynamic, cross-functional teams across international markets and navigate complex regulatory and commercial landscapes.